Nothing Special   »   [go: up one dir, main page]

Feld et al., 2005 - Google Patents

Mechanism of action of interferon and ribavirin in treatment of hepatitis C

Feld et al., 2005

Document ID
15240717641358301045
Author
Feld J
Hoofnagle J
Publication year
Publication venue
Nature

External Links

Snippet

Since the identification of the hepatitis C virus, great strides have been made in the development of an antiviral therapy. As a crucial mediator of the innate antiviral immune response, interferon-α (IFN-α) was a natural choice for treatment. Whereas treatment with …
Continue reading at www.nature.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha

Similar Documents

Publication Publication Date Title
Feld et al. Mechanism of action of interferon and ribavirin in treatment of hepatitis C
Heim 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end
Lanford et al. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly (i)-poly (c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons
Hofmann et al. Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms
Erhardt et al. Treatment of chronic hepatitis delta with pegylated interferon‐α2b
Chevaliez et al. Analysis of ribavirin mutagenicity in human hepatitis C virus infection
Manns et al. The way forward in HCV treatment—finding the right path
Nyström et al. Ribavirin: pharmacology, multiple modes of action and possible future perspectives
Zhou et al. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA
Sarrazin et al. Late relapse versus HCV reinfection in patients with sustained virologic response after sofosbuvir-based therapies
Lee et al. New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials
Thomas et al. The application and mechanism of action of ribavirin in therapy of hepatitis C
Te et al. Mechanism of action of ribavirin in the treatment of chronic hepatitis C
Diago et al. Association of pretreatment serum interferon γ inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C
Di Bisceglie et al. Ribavirin as therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial
Tam et al. Mechanisms of action of ribavirin in antiviral therapies
Yang et al. Interferon alpha (IFNα)-induced TRIM22 interrupts HCV replication by ubiquitinating NS5A
Pawlotsky Current and future concepts in hepatitis C therapy
Zhu et al. Interleukin-1 inhibits hepatitis C virus subgenomic RNA replication by activation of extracellular regulated kinase pathway
Friborg et al. Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication
Dahari et al. Hepatitis C viral kinetics in the era of direct acting antiviral agents and interleukin-28B
Kayali et al. Finally sofosbuvir: an oral anti-HCV drug with wide performance capability
Lee Daclatasvir: potential role in hepatitis C
Gentile et al. Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection
Barnes et al. Impact of alpha interferon and ribavirin on the function of maturing dendritic cells